COSM vs CODA vs HROW vs MNDO vs PAHC

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -9. 3% for MIND C. T. I. Ltd (MNDO). MIND C. T. I. Ltd (MNDO) offers the better valuation at 7. 8x trailing P/E, making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, MIND C.

T. I. Ltd (MNDO) is the cheapest at 7. 8x versus Phibro Animal Health Corporation at 36. 3x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Phibro Animal Health Corporation wins at 1. 75x versus Coda Octopus Group, Inc. 's 5. 33x — a reasonable growth-adjusted valuation.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -94. 5% for Cosmos Health Inc. (COSM). Over 10 years, the gap is even starker: HROW returned +893. 0% versus COSM's +30. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MIND C.

T. I. Ltd (MNDO) is the lower-risk stock at 0. 05β versus Harrow Health, Inc. 's 2. 08β — meaning HROW is approximately 3948% more volatile than MNDO relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -9. 3% for MIND C. T. I. Ltd (MNDO). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -43. 5% for MIND C. T. I. Ltd. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -29. 7% for Cosmos Health Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -28. 6% for COSM. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Phibro Animal Health Corporation (PAHC) is the more undervalued stock at a PEG of 1. 75x versus Coda Octopus Group, Inc. 's 5. 33x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 13. 1x forward P/E versus 81. 1x for Harrow Health, Inc. — 68. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

In this comparison, COSM (92.

4% yield), MNDO (21. 6% yield), PAHC (1. 1% yield) pay a dividend. CODA, HROW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, MIND C.

T. I. Ltd (MNDO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 21. 6% yield). Harrow Health, Inc. (HROW) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNDO: +65. 7%, HROW: +893. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (COSM (Healthcare) and CODA (Industrials) and HROW (Healthcare) and MNDO (Technology) and PAHC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: COSM is a small-cap income-oriented stock; CODA is a small-cap high-growth stock; HROW is a small-cap high-growth stock; MNDO is a small-cap deep-value stock; PAHC is a small-cap high-growth stock. COSM, MNDO, PAHC pay a dividend while CODA, HROW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.